Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2001-07-27
2009-08-04
Whiteman, Brian (Department: 1635)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
Reexamination Certificate
active
07569218
ABSTRACT:
Methods of delivering a desired polypeptide to an individual are disclosed. The methods comprise administering to the individual an immunogenic vector comprising a nucleic acid encoding the desired polypeptide operably linked to regulatory elements in combination with one or more of gD protein, a function fragment of gD protein, a nucleic acid encoding gD protein operably linked to regulatory elements, or a nucleic acid encoding a functional fragment of gD protein operably linked to regulatory elements. Compositions comprising an immunogenic vector that comprises a nucleic acid encoding the desired polypeptide operably linked to regulatory elements; and one or more of gD protein, a function fragment of gD protein, a nucleic acid encoding gD protein operably linked to regulatory elements, or a nucleic acid encoding a functional fragment of gD protein operably linked to regulatory elements are disclosed. Methods for inhibiting an undesirable immune response in an individual are disclosed.
REFERENCES:
patent: 4235871 (1980-11-01), Papahdjopoulos et al.
patent: 4241046 (1980-12-01), Papahdjopoulos et al.
patent: 4394448 (1983-07-01), Szoka et al.
patent: 4945050 (1990-07-01), Sanford et al.
patent: 5036006 (1991-07-01), Sanford et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5583028 (1996-12-01), Paoletti
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5593972 (1997-01-01), Weiner et al.
patent: 5614503 (1997-03-01), Chaudhary et al.
patent: 5622712 (1997-04-01), Eppstein et al.
patent: 5676954 (1997-10-01), Brigham
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5707618 (1998-01-01), Armentano et al.
patent: 5739118 (1998-04-01), Carrano et al.
patent: 5756283 (1998-05-01), Wilson et al.
patent: 5837533 (1998-11-01), Boutin
patent: 5955088 (1999-09-01), Ghiasi et al.
patent: 5958895 (1999-09-01), Pachuk et al.
patent: 6290949 (2001-09-01), French et al.
patent: 6355247 (2002-03-01), Selby et al.
patent: WO90/11092 (1990-10-01), None
patent: WO93/17706 (1993-09-01), None
patent: WO 96/11277 (1996-04-01), None
patent: WO99/43839 (1999-09-01), None
Zheng et al. Vaccine, 11:1191-1198, 1993.
Kafri et al. PNAS 95: 11377-11382, 1998.
Sin, J.I., et al., “Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune response against herpes simplex virus-2 through codelivery of granulocyte-macrophage colony-stimulating factor expression cassettes,” Eur. J. Immunol. (1998) 28: 3530-3540.
Ruitenberg, K.M., et al., “A prime-boost immunization strategy with DNA and recombinant baculovirus-expressed protein enhances protective immunogenicity of glycoprotein D of equine herpesvirus 1 in naive and infection-primed mice,” Vaccine (2000) 18:1367-1373.
Zhu, et al., “A chimeric protein comprised of bovine herpesvirus type 1 glycoprotein D and bovine interleukin-6 is secreted by yeast and possesses biological activities of both molecules,” Vaccine (1999) 17:269-282.
Sin, et al., “In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a Herpes simplex virus type 2 mouse model,” J. Virol. (1999) 73:501-509.
Sin, et al., “IL-12 gene as a DNA vaccine adjuvant in a Herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against Herpes simplex virus-2 challenge,” J. Immunol. (1999) 162:2912-2921.
Flo, et al., “Modulation of the immune response to DNA vaccine by co-delivery of costimulatory molecules,” Immunology (2000) 100:259-267.
Hazama, et al., “Adjuvant-independent enhanced immune responses to recombinant herpes simple virus-type 1 glycoprotein D by fusion with biologically active interleukin-2,” Vaccine (1993) 11:629-636.
Liljeqvist and Stahl, “Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines,” J. Biotechnol. (1999) 1-33.
Kim and Weiner, “Development of multicomponent DNA vaccination strategies against HIV,” Curr. Opin. Mol. Therap. (1998) 1:43-49.
Sin Jeong-Im
Weiner David B.
Pepper Hamilton LLP
The Trustees of the University of Pennsylvania
Whiteman Brian
LandOfFree
Compositions for and methods of using herpes simplex virus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for and methods of using herpes simplex virus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for and methods of using herpes simplex virus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4134657